EUDA Health Announces Second Amendment to Streeterville Warrant Agreement
EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform
EUDA Health (NASDAQ:EUDA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement
EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital